[Abstract]The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) has concluded. Several significant studies on the treatment of esophageal and gastroesophageal junction (GEJ) cancer were presented at the symposium, highlighting notable advances, particularly in the perioperative and advanced settings. Immunotherapy has demonstrated significant promise in the neoadjuvant treatment of esophageal cancer, showing potential to become a standard of care. Furthermore, the long-term survival benefits of combining immunotherapy with chemotherapy for advanced GEJ cancer were further validated. This article summarizes and interprets the research presented at the symposium concerning perioperative and advanced treatments for esophageal and GEJ cancers.